On September 22, 2015, FDA is conducting a public meeting on Patient-Focused Drug Development for Huntington’s disease and Parkinson’s disease. FDA is interested in obtaining patients’ perspectives on the impact of patient perspectives on the impact of Huntington’s disease and Parkinson’s disease on daily life and patient views on treatment approaches.
Although these are both neurological diseases, since they are quite distinct, FDA will structure this public meeting into two distinct sessions. The morning session, scheduled from 9 a.m. to 12:30 p.m., will be devoted to Huntington’s disease. The afternoon session, scheduled from 1:30 p.m. to 5 p.m., will be devoted to Parkinson’s disease.
This website will be updated as registration and additional meeting information become available.
September 22, 2015
9:00 a.m. to 5:00 p.m.
FDA White Oak Campus
10903 New Hampshire Ave.
Bldg. 31 Conference Center (the Great Room)
Silver Spring, MD 20993-0002
To register for this meeting, visit: Register online
Registration to attend the meeting must be received by September 14, 2015.
Huntington's Disease - Voice of the Patient (Public Meeting: September 22, 2015) (PDF - 385KB)
Webinar: Background on FDA and Patient-Focused Drug Development[ARCHIVED]
- Federal Register Notice
- Huntington's Disease Agenda (Morning) (PDF - 138KB)
- Parkinson's Disease Agenda (Afternoon) (PDF - 203KB)
Meeting Slides(PDF - 526KB) Meeting Recording Part 1 Meeting Recording Part 2 Meeting Recording Part 3 Meeting Recording Part 4 The Voice of the Patient: Huntington’s Disease(PDF - 407KB)
- The Voice of the Patient: Parkinson's Disease (PDF - 319KB)